Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M515Revenue $M79.9Net Margin (%)66.0Altman Z-Score4.0
Enterprise Value $M368EPS $1.1Operating Margin %65.7Piotroski F-Score5
P/E(ttm)10.8Beneish M-Score2.1Pre-tax Margin (%)66.0Higher ROA y-yY
Price/Book3.410-y EBITDA Growth Rate %--Quick Ratio3.8Cash flow > EarningsN
Price/Sales6.25-y EBITDA Growth Rate %--Current Ratio3.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)34.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)56.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M41.8ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with VNDA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VNDAJohn Paulson 2015-06-30 Reduce$9.09 - $13.42
($10.76)
$ 12.1813%Reduce 0.09%3,946,500
VNDAJohn Paulson 2015-03-31 Add0.02%$8.99 - $14.58
($11.3)
$ 12.188%Add 8.97%3,950,000
VNDAJohn Paulson 2014-06-30 Add0.12%$9.7 - $16.96
($13.27)
$ 12.18-8%Add 129.80%3,200,000
VNDAJohn Paulson 2014-03-31 Buy 0.11%$10.5 - $18.71
($14.13)
$ 12.18-14%New holding1,392,500
VNDAFirst Eagle Investment 2013-09-30 Sold Out -0.02%$8.05 - $13.031
($10.72)
$ 12.1814%Sold Out0
VNDAFirst Eagle Investment 2013-06-30 Reduce-0.01%$3.93 - $13
($6.73)
$ 12.1881%Reduce 48.99%975,000
VNDAFirst Eagle Investment 2012-12-31 Add0.01%$3.03 - $4.16
($3.54)
$ 12.18244%Add 43.16%1,911,452
VNDAFirst Eagle Investment 2010-03-31 Add0.04%$10.01 - $12.38
($10.94)
$ 12.1811%Add 111.12%752,375
VNDAFirst Eagle Investment 2009-12-31 Buy 0.04%$9.59 - $11.84
($10.79)
$ 12.1813%New holding356,375
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VNDA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VNDA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Polymeropoulos Mihael HristosPresident and CEO 2015-05-22Sell186,395$10.3617.57view
Polymeropoulos Mihael HristosPresident and CEO 2015-03-10Sell21,900$10.5315.67view
Kelly James PatrickSVP, CFO, Sec & Treasurer 2015-03-10Sell12,450$10.5315.67view
Baroldi PaoloSVP & Chief Medical Officer 2015-03-10Sell8,940$10.5415.56view
DUGAN RICHARD WDirector 2015-03-09Sell4,804$10.6913.94view
Flynn James E 2014-12-23Buy162,014$14.4-15.42view
Watkins ThomasDirector 2014-03-14Sell35,000$17.66-31.03view
Repella RobertSVP & Chief Commercial Officer 2013-11-21Sell107,500$12.031.25view
Polymeropoulos Mihael HristosPresident and CEO 2013-11-19Sell8,928$12.070.91view
Kelly James PatrickSVP, CFO, Sec & Treasurer 2013-11-19Sell3,348$12.070.91view

Quarterly/Annual Reports about VNDA:

    News about VNDA:

    Articles On GuruFocus.com
    Weekly CEO Sells Highlight: Walker & Dunlop, Arista Networks, Vanda Pharmaceuticals, and Synopsys May 31 2015 
    John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
    Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
    comment on VNDA Nov 12 2012 
    Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
    Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
    $VNDA New study started: Oct 15 2010 
    Hourly trend UP Aug 11 2010 
    Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
    upgraded to BUY Jul 07 2010 

    More From Other Websites
    Vanda Pharmaceuticals, Inc. Earnings Q2, 2015 Aug 26 2015
    Why Vanda Pharmaceuticals (VNDA) Could Be a Potential Winner Aug 20 2015
    Is Volatility in Asian Markets Here to Stay? Aug 19 2015
    What's Driving the Global Markets? Aug 18 2015
    Vanda Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference Aug 10 2015
    VANDA PHARMACEUTICALS INC. Financials Aug 07 2015
    HETLIOZ® (tasimelteon) Phase III SET and RESET Trial Results Published in The Lancet Aug 05 2015
    10-Q for Vanda Pharmaceuticals, Inc. Aug 03 2015
    Vanda Announces Listing of Four New Fanapt® Patents in the FDA Orange Book Aug 03 2015
    Vanda Pharmaceuticals (VNDA) Jumps: Stock Moves Up 8.4% - Tale of the Tape Jul 31 2015
    VANDA PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report Jul 31 2015
    Edited Transcript of VNDA earnings conference call or presentation 29-Jul-15 8:30pm GMT Jul 29 2015
    Vanda reports 2Q loss Jul 29 2015
    Vanda reports 2Q loss Jul 29 2015
    Vanda Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Jul 29 2015
    VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 29 2015
    Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results Jul 29 2015
    Q2 2015 Vanda Pharmaceuticals Inc Earnings Release - After Market Close Jul 29 2015
    Vanda Pharmaceuticals to Announce Second Quarter 2015 Financial Results on July 29, 2015 Jul 09 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK